In addition to non-clinical studies, the beneficial effects of modulating TRPV1, TRPA1 and TRPC5 channels in obesity, T2D, atherosclerosis and MS have been investigated in a range of clinical trials. Here, TRPC5 is linked to obesity due to melanocortin 4 receptor deficiency.